Linear Clinical Research is an award-winning medical research facility located at QEII Medical Centre in Perth. They are conducting a study on the effect of baclofen vs placebo on the activation of the mesolimbic dopaminergic system in methamphetamine dependent subjects: fMRI study.
Methamphetamine addiction is a major and growing problem in Australia, with a considerable individual, family and community burden. The current trend is a rapid increase in the use of crystal methamphetamine, the most addictive form, from 10% of users in 2010 to over 50% in 2014. Current treatment options for methamphetamine addiction are all based on Cognitive Behavioural Therapy (CBT) and have very low rates of durable abstinence.
Linear Clinical Research Ltd, is testing Baclofen to establish if Baclofen has an anti-craving action in methamphetamine. To test this anti-craving action, Magnetic Resonance Images (MRI) of brain activation will be assessed in Baclofen treated participants compared to placebo. Participants in the study will continue to take Baclofen for 28 days after an initial 7 days in the Linear Clinical Research unit. After this time, they will be offered the option of taking Baclofen for another 11 months to complete the study period to
assess the effect of Baclofen on cravings over this time period. This study does not provide any remuneration for its participants. Participants are required to stay in Linear’s clinic for 7 days.
To qualify for this trial, candidates must pass the inclusion and exclusion criteria. See below for some of the criteria included.